Prostate Cancer — Expanded Access Programs

• Study on 177Lu-J591 and Ketoconazole for Prostate Cancer Treatment — Weill Medical College of Cornell University
• Study on 18F-DCFPyL PET/CT Imaging for High Risk and Recurrent Prostate Cancer — National Cancer Institute (NCI)
• Study on Using 18F-DCFPyL PET/MRI to Detect Tumors in Intermediate and High-Risk Prostate Cancer — Stanford University
• Study on 64Cu-SAR-bisPSMA PET/CT for Detecting Prostate Cancer Recurrence — Clarity Pharmaceuticals Ltd
• Study on Ifinatamab Deruxtecan (I-DXd) for Treating Metastatic Prostate Cancer — Merck Sharp & Dohme LLC
• Study on Combining Hormone Therapy, PARP Inhibitor, and Radiation for Prostate Cancer — University of Michigan Rogel Cancer Center
• Study on ST101 for Patients with Advanced Solid Tumors — Sapience Therapeutics
• Phase 2 Study on the Effects of ASP5541 in Men with Advanced Prostate Cancer — Astellas Pharma Global Development, Inc.
• Pilot Study of REGN5678 for High-Risk Prostate Cancer Before Surgery — M.D. Anderson Cancer Center
• A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer — Matrix Biomed, Inc.
• Study on Using a New Fluorescent Imaging Technique for Prostate Cancer Diagnosis — Antelope Surgical Solutions, Inc
• Study for Prostate Cancer Patients Who Previously Participated in an Enzalutamide Clinical Trial — Astellas Pharma Global Development, Inc.
• Study on 2141-V11 Combined with Standard Treatments for Prostate Cancer — Memorial Sloan Kettering Cancer Center
• Study on Abiraterone Acetate and Prednisone With or Without Abemaciclib for Prostate Cancer — Eli Lilly and Company
• Study on Apalutamide Plus Hormone Therapy Versus Hormone Therapy Alone for Metastatic Hormone-Sensitive Prostate Cancer — Aragon Pharmaceuticals, Inc.
• Study on BMS986365 and Degarelix for Prostate Cancer Treatment — Memorial Sloan Kettering Cancer Center
• Study on Enzalutamide and Relacorilant for High-Risk Localized Prostate Cancer — University of Chicago
• Study on HER3-DXd for Advanced or Metastatic Solid Tumors — Daiichi Sankyo
• Study on Lower Dose Radiation Therapy for Prostate Cancer — Memorial Sloan Kettering Cancer Center
• Study on Saruparib vs Placebo with Radiation and Hormone Therapy for High-Risk Prostate Cancer with BRCA Mutation — AstraZeneca
• Study on MRI-guided High-dose Radiation Therapy for Prostate Cancer — Memorial Sloan Kettering Cancer Center
• Study on MT-4561 for Patients with Advanced Solid Tumors — Mitsubishi Tanabe Pharma America Inc.
• Study on PARG Inhibitor ETX-19477 for Patients with Advanced Solid Cancers — 858 Therapeutics, Inc.
• Study on Salvage Radiotherapy With or Without Enzalutamide for Recurrent Prostate Cancer After Surgery — RTOG Foundation, Inc.
• Study on Stereotactic Body Radiation Therapy Without Hormone Therapy for Unfavorable Intermediate-Risk Prostate Cancer — Memorial Sloan Kettering Cancer Center
• Study on Tinengotinib Combined with Standard Treatments for Prostate Cancer — Memorial Sloan Kettering Cancer Center
• Study on APL-5125 for Adults with Advanced Solid Tumors — Apollo Therapeutics Ltd
• Study on the Safety and Effectiveness of AZD6621 in Men with Advanced Prostate Cancer — AstraZeneca
• Study on Radium-223 and Docetaxel for Prostate Cancer Treatment — Memorial Sloan Kettering Cancer Center
• Study on AMXI-5001 for Treating Advanced Cancers — AtlasMedx, Incorporated
• Study on Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer — Wake Forest University Health Sciences
• Study on the Safety and Effectiveness of AZD9750 for Metastatic Prostate Cancer, Alone or with Other Cancer Drugs — AstraZeneca
• Study Comparing Abiraterone/Prednisone with Standard Hormone Therapy for Prostate Cancer Patients with PSMA-Positive but Conventional Imaging Negative Pelvic Lymph Nodes — University of Nebraska
• Study on Using Curcumin to Improve Cancer-Free Survival After Prostate Surgery — yair lotan
• Study Comparing Hormone Therapy and Radiation vs. Radiation Alone for Unfavorable Intermediate Risk Prostate Cancer — NYU Langone Health
• Study on Using Cryotherapy to Target and Treat Intermediate Risk Prostate Cancer — M.D. Anderson Cancer Center
• Study on Androgen Deprivation with or without pTVG-AR Vaccine and T-Cell Checkpoint Blockade for High-Risk Prostate Cancer — University of Wisconsin, Madison
• Study on Combining Hormone Therapy with Targeted Radiation and Increased Dose Prostate Treatment — Canadian Cancer Trials Group
• Study on Androgen-Deprivation Therapy and Radiation Therapy for Prostate Cancer Treatment — Radiation Therapy Oncology Group
• Study on Using POSLUMA Imaging to Improve Radiation Treatment for Prostate Cancer — Martin T. King, MD, PhD
• Study on the Anti-Tumor Effects of (177Lu) rhPSMA-10.1 Injection for Advanced Prostate Cancer — Blue Earth Therapeutics Ltd
• Study on the Effectiveness of Hormone Therapy Before Surgery in High-Risk Prostate Cancer Using a Special PET/CT Scan — Baptist Health South Florida
• Study on Atezolizumab and Tivozanib for Treating Certain Hard-to-Treat Cancers — University of Florida
• Study on Axelopran for Advanced Cancer in Patients Using Opioids — HealthPartners Institute
• Study on the Use of Ga-68 P16-093 for Prostate Cancer Imaging — Five Eleven Pharma, Inc.
• Study on Brachytherapy for Prostate Cancer Patients — M.D. Anderson Cancer Center
• Study on Enhertu Therapy for Castration-Resistant Prostate Cancer — Washington D.C. Veterans Affairs Medical Center
• Study on Green Tea Extracts for Men Under Active Surveillance for Prostate Cancer — H. Lee Moffitt Cancer Center and Research Institute
• Study on Combining Ipilimumab with Abiraterone Acetate and Prednisone for Patients with Advanced Prostate Cancer — Memorial Sloan Kettering Cancer Center
• Study on Testosterone Recovery After Androgen Deprivation Therapy with Relugolix and Darolutamide (CLEARED) — Atish Choudhury, MD
• Study Comparing Two Boost Methods in Radiation Therapy for Prostate Cancer — Memorial Sloan Kettering Cancer Center
• Study on Darolutamide with Standard Therapy for High-Risk Localized Prostate Cancer — University of Sydney
• Study on the Use of rhPSMA-7.3 (18F) PET/CT for Men with Prostate Cancer Under Active Surveillance — Icahn School of Medicine at Mount Sinai
• Study on Difluoromethylornithine and High Dose Testosterone with Enzalutamide for Advanced Prostate Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Study on MDX2001 for Patients with Advanced Solid Tumors — ModeX Therapeutics, An OPKO Health Company
• Early Access Program for HER2/HER3 Bispecific Antibody MCLA-128 for Patients with Advanced NRG1-Fusion Positive Solid Tumors — Merus N.V.
• Study on Combining External and Internal Radiation Therapy for High-Risk Prostate Cancer — University of Virginia
• Study on Enzalutamide and M9241 for Recurrent Prostate Cancer Without Lowering Testosterone — National Cancer Institute (NCI)
• Study on How Race and Other Factors Affect Response to Abiraterone/Prednisone in Men with Metastatic Hormone-Naive Prostate Cancer — Martha Mims
• Access to 68Gallium-PSMA-11 PET Imaging for Prostate Cancer Detection and Treatment Planning — University of California, San Francisco
• Program to Access Botensilimab and Balstilimab Before Official Approval — Agenus Inc.
• Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer — Jeanne Link
• Expanded Access to 68Ga-PSMA-11 PET Imaging for Prostate Cancer Detection — Jonsson Comprehensive Cancer Center
• Access to AVM0703 for Patients with Solid Tumors and Blood Cancers — AVM Biotechnology Inc
• Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer — Wake Forest University Health Sciences
• Study on FK-PC101 Vaccine as Additional Treatment for Men with High-Risk Prostate Cancer — Cellvax Therapeutics Inc
• Study on Radiation and Hormone Therapy with Chemotherapy for Treating Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) — University of Michigan Rogel Cancer Center
• Focal Therapy with Stereotactic Body Radiation Therapy (SBRT) for Patients with a Single Prostate Tumor — National Cancer Institute (NCI)
• Study on FOR46 and Enzalutamide for Treating Advanced Prostate Cancer — Rahul Aggarwal
• Study on Gedatolisib and Darolutamide for Treating Metastatic Castration-Resistant Prostate Cancer — Celcuity Inc
• Study on Genomic Biomarker-Selected Treatment Before Surgery for High-Risk Localized Prostate Cancer — University of British Columbia
• Study on Glycyrrhizin for Prostate Cancer Treatment — University of Illinois at Chicago
• Study on HER2 FPBMC Treatment for Patients with Metastatic Breast and Prostate Cancer — University of Virginia
• Study on High Intensity Focused Ultrasound for Prostate Cancer — University of Florida
• Study on High-Risk Metachronous Oligometastatic Prostate Cancer — University of Maryland, Baltimore
• Study on Using Hyperpolarized 13C MRI to Monitor Response to Abiraterone Treatment in Prostate Cancer — Ivan de Kouchkovsky, MD
• Study on Hypo-fractionated Radiation Therapy With or Without Hormone Therapy for Intermediate Risk Prostate Cancer — Proton Collaborative Group
• Study on Hypofractionated Radiotherapy with a Targeted Boost for High-Risk and Locally Advanced Prostate Cancer — Medical University of South Carolina
• Study on Shortened Proton Therapy with Internal Radiation Boost for High-Risk Prostate Cancer — Abramson Cancer Center at Penn Medicine
• Study on Image-Guided, Tumor-Focused Radiotherapy for Intermediate and High-Risk Prostate Cancer — University of California, San Diego
• Study on the Impact of Fluciclovine (18F) PET Scans for Prostate Cancer Management After Inconclusive PSMA PET Imaging — Blue Earth Diagnostics
• Study on Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer — Cedars-Sinai Medical Center
• Study on Preserving Erectile Function in Intermediate Risk Prostate Cancer Treatment — Dana-Farber Cancer Institute
• Long-Term Study for Participants Continuing Treatment from a Previous Exelixis Study — Exelixis
• Long-Term Safety Study of Lutetium (177Lu) Vipivotide Tetraxetan in Prostate Cancer Patients — Novartis Pharmaceuticals
• Study on Using Advanced MRI with Hyperpolarized 13C-Pyruvate and 13C,15N-Urea for Prostate Cancer Patients — Robert Bok, MD, PhD
• Study on Radiation Therapy and Hormone Treatment for Metastatic Prostate Cancer in the STAMPEDE Trial (METANOVA) — Case Comprehensive Cancer Center
• Study on MRI-based Targeted Radiation Therapy for Low to Intermediate Risk Prostate Cancer — Georgetown University
• Phase II Study of sEphB4-HSA and Pembrolizumab for Treating Solid Tumors — University of Southern California
• Study on Neoadjuvant ADT, Darolutamide, and Pembrolizumab for High-Risk Prostate Cancer — Icahn School of Medicine at Mount Sinai
• Study on Atezolizumab-Based Combination Therapy Before Surgery for Men with Localized Prostate Cancer — David Oh
• Study on Pembrolizumab and Androgen Blockade Before Surgery for High-Risk Localized Prostate Cancer — Mark Garzotto, MD
• Study on Hormone Therapy with or without Additional Drugs for Prostate Cancer — Jonsson Comprehensive Cancer Center
• NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial — M.D. Anderson Cancer Center
• Study on Nivolumab and BMS-986253 for Treating Hormone-Sensitive Prostate Cancer (MAGIC-8) — Mark Stein
• Study on Nivolumab for Patients with High-Risk Recurrent Prostate Cancer — Beth Israel Deaconess Medical Center
• Study Comparing AAA817 with Standard Treatment for Advanced Prostate Cancer in Adults Who Have Previously Received PSMA Therapy — Novartis Pharmaceuticals
• Study on Pocenbrodib Alone and in Combination with Other Treatments for Advanced Prostate Cancer — Pathos AI, Inc.
• Study on Pacritinib for Metastatic Castrate-Resistant Prostate Cancer After Androgen Receptor Treatment — Medical College of Wisconsin
• Study on Pembrolizumab with Radiation, with or without Olaparib, for High-Risk Localized Prostate Cancer — Zin W Myint
• Study on Pembrolizumab and 177Lu-PSMA-617 for Treating Advanced Prostate Cancer — University of California, San Francisco
• Study on How Genetic Differences Affect the Effectiveness and Safety of Abiraterone in Prostate Cancer Treatment — Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
• Study on Pembrolizumab and Androgen-receptor Pathway Inhibitor with or without 225Ac-J591 for Advanced Prostate Cancer — Weill Medical College of Cornell University
• Phase II Study on Gene and Hormone Therapies, Radiation, and Surgery for High-Risk Prostate Cancer — The Methodist Hospital Research Institute
• Phase II Study on Monitoring Prostate Cancer with PSMA-PET and Radiotherapy — City of Hope Medical Center
• Phase II Study of Proton Beam Radiation Therapy for Prostate Cancer — The New York Proton Center
• Phase II Study on PSA Response-Based Treatment and Nodal Coverage for Early Salvage Radiotherapy in Prostate Cancer — University of Texas Southwestern Medical Center
• Study on Photodynamic Therapy for Localized Prostate Cancer Using the SpectraCure P18 System — SpectraCure AB
• Study on PET Scans Using 64Cu-SAR-bisPSMA for Detecting Cancer Spread in High-Risk Prostate Cancer Patients Before Surgery — Clarity Pharmaceuticals Ltd
• Study Comparing Two Types of Radiation Therapy After Prostate Surgery: Moderate vs. Ultra-hypofractionated (SBRT) — University of Michigan Rogel Cancer Center
• Study on Talazoparib and Enzalutamide Before Surgery for Prostate Cancer — M.D. Anderson Cancer Center
• Study on Prostate Cancer Treatment Using Hormone Therapy and Targeted Prostate Surgery — University of Chicago
• PROSTATE-IQ: Study on Personalized Apalutamide Treatment to Improve Quality of Life in Men with Detectable PSA After Prostate Surgery for Prostate Cancer — M.D. Anderson Cancer Center
• Study on PSMA-Directed Radiation Therapy for Recurrent Prostate Cancer — University of Miami
• Study on Using PSMA-PET to Guide Reduced Radiation Treatment for Recurrent Prostate Cancer After Surgery — University of Nebraska
• Study on pTVG-HP and Nivolumab for Patients with Non-Metastatic Prostate Cancer — University of Wisconsin, Madison
• Study on PyL Imaging for Detecting High Risk and Recurrent Prostate Cancer — Hoag Memorial Hospital Presbyterian
• Study on PYLARIFY® PET/CT or PET/MRI for Men with Favorable Intermediate Risk Prostate Cancer — Lantheus Medical Imaging
• Study on Targeted Radiation Without Hormone Therapy for Advanced Prostate Cancer — VA Office of Research and Development
• Study Comparing Relugolix and Leuprolide for Quality of Life in Prostate Cancer Patients — Dana-Farber Cancer Institute

Looking for a program not shown above? Search the full catalog for “Prostate Cancer” to see every match including additional filters.